Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease
2011 C.A.R.E. (Commitment to Alzheimer's. Recognition of Excellence.) Pharmacy Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care

WOODCLIFF LAKE, NJ, November 8, 2011 - Eisai Inc. and the Alzheimer's Association announce today that Max C. Brown, RPh is the recipient of the 2011 C.A.R.E. Pharmacy Award.

Mr. Brown has been the owner of Max Brown Pharmacy in Dublin, GA since its opening in October 1973. The ballot supporting his nomination describes him as a "generous and caring pharmacist," one that is held in “high regard” within the community. He is well recognized for his "knowledge of the effects of Alzheimer's medications and a variety of Alzheimer's patient symptoms." Mr. Brown received his degree from the University of Georgia.

The C.A.R.E. Pharmacy Award recognizes the extraordinary impact that pharmacists can have on the lives of individuals with Alzheimer's disease and their families. Now in its eleventh year, the award is a reflection of Eisai's human health care (hhc) mission, which is to give first thought to patients and their families, and to helping increase the benefits that health care provides.

"Alzheimer's disease can be devastating to patients as well as caregivers. We view pharmacists as valued partners in the delivery of quality health care, appropriate medication, counseling and support to these patients and their families," said Lonnel Coats, President & CEO of Eisai Inc. "In partnering with the Alzheimer's Association on the C.A.R.E. Pharmacy Award, we proudly recognize the recipient for his extraordinary effort in enhancing the quality of care for people affected by this disease."

"We are pleased to congratulate this year's winner, Max Brown, for his dedication and understanding of the Alzheimer's community," said Cyndy Cordell, Director of Healthcare Professional Services at the Alzheimer's Association and a member of the C.A.R.E. Pharmacy Award selection committee. "The Alzheimer's Association is honored to be a part of the C.A.R.E. Pharmacy Award since its inception in 2008 and we greatly appreciate the generous support provided by Eisai Inc. to make this award possible."

A donation of $2,500 will be made to the Perry, GA Chapter of the Alzheimer's Association, which serves the area where Mr. Brown works.

About Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

About the Alzheimer's Association

The Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. For more information, visit www.alz.org.

Type Press Release

Date Released November 08, 2011

Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
* Required Fields